EU PV Regulatory Intelligence news: EU Commission Implementing Regulation 2025/1466 Other
guides
NextPV Services
  • Safety Corner
  • Articles
  • Preparation of pharmacovigilance regulatory documents: PSURs/PBRERs, RMPs, DSURs, ACO

Preparation of pharmacovigilance regulatory documents: PSURs/PBRERs, RMPs, DSURs, ACO

What are PSURs, RMPs, and DSURs — and when does your company need to submit them?

Pharmacovigilance regulatory documents — PSURs/PBRERs, Risk Management Plans, DSURs, and the Addendum to the Clinical Overview — are how marketing authorization holders (MAHs) communicate the safety profile and benefit-risk balance of their products to regulators. These are not optional documents; they have legally mandated formats, content requirements, and submission timelines.

This article covers the regulatory basis, content structure, and practical advice for each document type.

PSURs/PBRERs: Periodic Benefit-Risk Evaluation

Regulatory Basis

The Periodic Safety Update Report (PSUR), now formally called the Periodic Benefit-Risk Evaluation Report (PBRER) under ICH terminology, is required under EU Directive 2001/83/EC and detailed in ICH E2C(R2) and EMA GVP Module VII.

Purpose

The PSUR/PBRER provides a comprehensive, periodic assessment of the worldwide safety experience of a medicinal product. It is not just a listing of adverse events — it requires a critical evaluation of the benefit-risk balance, incorporating new safety data, exposure information, and any changes to the known safety profile.

Content Structure (per ICH E2C(R2))

  • Introduction: Product identification, reporting period, authorization status
  • Worldwide marketing authorization status: Where the product is marketed and under what conditions
  • Actions taken for safety reasons: Regulatory actions, product label changes, withdrawals
  • Changes to Reference Safety Information: Modifications to the SmPC safety sections during the reporting period
  • Estimated exposure and use patterns: Patient exposure data (calculated from sales data, prescription data, or clinical trial data)
  • Data in summary tabulations: Tabular presentation of all ICSRs received during the reporting period
  • Summaries of significant safety findings: From clinical trials; from spontaneous reporting (including cumulative and interval analysis); from literature; from other sources (registries, observational studies)
  • Signal and risk evaluation: New signals identified during the reporting period; evaluation of ongoing signals; assessment of identified and potential risks; evaluation of risk minimization measure effectiveness
  • Benefit evaluation: Assessment of the product's therapeutic benefits
  • Integrated benefit-risk analysis: The core section — a systematic assessment of whether the benefit-risk balance remains favorable
  • Conclusions and actions: Summary conclusions and any proposed actions (label changes, additional studies, risk minimization measures)

Submission Timelines

PSUR submission frequency is determined by the EU Reference Dates (EURD) list published by EMA. Typical frequencies:

  • Products authorized < 2 years: every 6 months
  • Products authorized 2–5 years: annually
  • Products authorized > 5 years: every 3 years (or as specified)

Submission is through the EMA's PSUR repository. Late submission is a compliance failure that may be flagged during inspections.

Practical Tips

  • Start preparation early — PSUR preparation typically requires 2–4 months for complex products. Begin data extraction at the start of the reporting period cutoff.
  • Signal integration — The PSUR must reflect all signal detection and assessment activities from the reporting period. Ensure signal management records are current and accessible.
  • Benefit-risk analysis — This is where many PSURs fall short. ICH E2C(R2) requires a structured benefit-risk analysis, not just a summary of safety data. Use a framework (e.g., EMA's benefit-risk methodology) to demonstrate systematic evaluation.

Risk Management Plans (RMPs)

Regulatory Basis

RMPs are required under Regulation (EC) No 726/2004 for centrally authorized products and EU Directive 2001/83/EC for nationally authorized products. The format and content are defined in EMA GVP Module V (EMA/838713/2011 Rev 2) and EMA GVP Module XVI (risk minimization measures).

RMP Structure (per GVP Module V)

Part I: Product Overview

  • Product/active substance information
  • Brief summary of the disease epidemiology

Part II: Safety Specification

  • Summary of the non-clinical and clinical safety profile
  • Identified risks: established safety concerns based on available evidence
  • Potential risks: safety concerns where evidence is suggestive but not conclusive
  • Missing information: populations or situations where safety data is insufficient (e.g., elderly, pediatric, pregnant, hepatic/renal impairment)

Part III: Pharmacovigilance Plan

  • Routine PV activities (signal detection, PSUR preparation, ICSR management)
  • Additional PV activities (PASS studies, registries, targeted follow-up questionnaires)

Part IV: Plans for Post-Authorization Efficacy Studies (PAES)

  • Studies specifically assessing effectiveness in real-world conditions

Part V: Risk Minimization Measures

  • Routine measures: SmPC, package leaflet, pack size
  • Additional measures: educational materials, controlled distribution, patient registries, pregnancy prevention programs
  • Evaluation of risk minimization effectiveness per GVP Module XVI

When RMPs Must Be Updated

  • At the request of a competent authority or EMA
  • When the safety specification changes (new identified risk, new potential risk)
  • When new risk minimization measures are needed
  • When a milestone is reached (e.g., PASS results available, risk minimization effectiveness data)
  • As part of the PSUR assessment (the PRAC may request RMP updates following PSUR review)

Development Safety Update Reports (DSURs)

Regulatory Basis

The DSUR is required for investigational products in active clinical development, defined by ICH E2F. In the EU, DSUR submission is mandated by the EU Clinical Trials Regulation (EU) 2014/536.

Key Differences from PSURs

  • PSUR/PBRER: Marketed products (post-authorization); reference document is SmPC; frequency per EURD list; regulatory basis ICH E2C(R2), GVP Module VII; submitted to PSUR repository
  • DSUR: Investigational products (clinical development); reference document is Investigator's Brochure; frequency annually from DIBD; regulatory basis ICH E2F, EU CTR; submitted to CTIS (EU) / directly to NCAs

DSUR Content (per ICH E2F)

  • Status of all ongoing and completed trials
  • Estimated cumulative subject exposure across all trials
  • Summary of significant safety findings (SUSARs, SAEs, safety signals)
  • Changes to the Reference Safety Information (IB updates)
  • Actions taken for safety reasons (protocol amendments, clinical holds)
  • Overall benefit-risk assessment in the context of the development program

Addendum to the Clinical Overview (ACO)

Purpose

The ACO is a concise document submitted as part of the MAA (marketing authorization application) dossier that bridges the gap between the data cutoff of the clinical development program and the MAA submission date. It provides an updated safety analysis based on the most recent available data.

Content

  • Summary of new safety data since the main clinical dossier cutoff
  • Updated integrated analysis of safety (if significant new data is available)
  • Updated benefit-risk assessment incorporating the latest safety information
  • Any new safety-related actions or protocol amendments

Practical Considerations

The ACO is typically prepared in the final months before MAA submission. Timing coordination between the clinical team (ongoing trials), PV team (safety data), and regulatory team (submission timeline) is critical.

Best Practices for Document Preparation

Cross-Functional Collaboration

PSURs, RMPs, DSURs, and ACOs require input from pharmacovigilance, clinical development, regulatory affairs, medical affairs, and biostatistics. Establish clear roles and timelines for each contributing function early in the preparation process.

Regulatory Intelligence

Monitor changes in regulatory expectations. EMA's PRAC regularly publishes updated guidance on PSUR and RMP requirements. Stay current with the EURD list for submission timelines.

Quality Control

Implement multi-step review processes: author review → medical review → quality review → final approval. Ensure version control and audit trails for all document drafts.

Timeline Management

Start early. PSURs typically need 2–4 months of preparation time. RMP updates should be initiated as soon as the trigger event occurs. DSURs should be in preparation 2–3 months before the DIBD anniversary. NextPV's medical writing team builds submission timelines into every project plan, with built-in review cycles to avoid last-minute rushes.

Conclusion

Pharmacovigilance regulatory documents are not administrative exercises — they are the formal mechanism through which MAHs demonstrate ongoing safety monitoring and benefit-risk management to regulators. The standards are defined by ICH E2C(R2), GVP Module V, GVP Module VII, and ICH E2F. Meeting these standards requires specialized writing expertise, access to comprehensive safety data, and rigorous quality processes.